Cell Signaling & Oncology
The signaling pathways controlling cell growth and differentiation are almost invariably altered in cancer. During the course of tumor progression, cancer cells acquire a number of characteristic alterations. These include the capacities to proliferate independently of exogenous growth-promoting or growth-inhibitory signals, to invade surrounding tissues and metastasize to distant sites, to elicit an angiogenic response, and to evade mechanisms that limit cell proliferation, such as apoptosis and replicative senescence. These properties reflect alterations in the cellular signaling pathways that in normal cells control cell proliferation, motility, and survival. These interconnected pathways are being deciphered, but understanding the alterations that lead to cancer and correcting them is a substantial challenge. Among the key pathways are those controlling cell proliferation, which coordinate a response to the cellular environment, with the mTOR kinase as a critical node. Tumour development is influenced by infections and inflammation, and the complex role of the nuclear factor-B transcription factors is being unravelled. Expansion of tumour cells depends on nutrient supply and vascularization, which is orchestrated by the transcription factor known as HIF. And the metastatic spread of primary tumours to other organs is facilitated by many signaling pathways[1],[2].
Cell Signaling and Oncology products Library
For your convenience, you can order a library of all of our Cell Signaling and Oncology research related products. Make your personal library by cherry picking products of your interest from our comprehensive list (>800 products), or order all together not to miss any. The libraries will be shipped as 10 mM solutions (in DMSO, 250 µL of each selected Axon Ligand™) on a 96-well microtiter plate with a clear map of its contents.
Simply download our comprehensive list of epigenetics products below (Microsoft Excel (.xls)), check the products to be included, and return your list to order the library of your preference.
 Axon 5051 - Cell signaling and Oncology Library.xls |
|
[1] A. Eccleston, R. Dhand. Signalling in cancer. Nature 441, 423, editorial note
[2] G.S. Martin. Cell signaling and cancer. Cancer Cell. 2003 Sep;4(3):167-74.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 1378 | AG 490 | JAK2 inhibitor | €65.00 | |
| 1778 | AZ 960 | JAK2 inhibitor | €95.00 | |
| 3855 | AZD-4205 | Selective and ATP-competitive inhibitor of JAK1 | Inquire | |
| 1955 | Baricitinib | Inhibitor of JAK1 and JAK2 | €70.00 | |
| 3813 | BMS-911543 | Potent, selective and orally active inhibitor of JAK2 | Inquire | |
| 3671 | CEP-33779 | Potent, selective and orally bioavailable JAK2 inhibitor | €95.00 | |
| 1338 | CP 690550 | JAK3 inhibitor | €60.00 | |
| 3861 | Decernotinib | Potent and selective,orally bioavailable Janus kinase 3 (JAK3) inhibitor | Inquire | |
| 4006 | GLPG-0634 | The first orally-available, selective inhibitor of JAK1 | Inquire | |
| 1843 | JAK2 inhibitor 13 | JAK2 inhibitor | €110.00 | |
| 2554 | LY 2784544 | Potent, selective and ATP-competitive inhibitor of mutated janus kinase 2 (JAK2V617F) | €95.00 | |
| 1681 | Momelotinib | JAK1 and JAK2 inhibitor | €80.00 | |
| 4124 | Momelotinib hydrochloride | JAK1 and JAK2 inhibitor | €120.00 | |
| 2792 | NVP-BSK805 | Potent, selective and orally bioavailable JAK2 inhibitor | €125.00 | |
| 2217 | PF 956980 | JAK3 inhibitor; analogue of Axon 1338 and 2072 | €90.00 | |
| 1598 | Ruxolitinib | JAK1 and JAK2 inhibitor | €65.00 | |
| 2539 | Solcitinib | Selective JAK1 inhibitor for treatment of degenerative and inflammatory diseases | €90.00 | |
| 1588 | TG 101348 | JAK2 inhibitor | €80.00 | |
| 2072 | Tofacitinib citrate | Potent Janus Kinase 3 (JAK3) inhibitor | €115.00 | |
| 2316 | WP 1066 | Potent JAK2 and STAT3 inhibitor and downregulator of antiapoptotic proteins | €95.00 | |
| 2231 | XL 019 | JAK2 inhibitor | €100.00 | |